drugset
drugset / Trial / NCT06346041

Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors

NCT06346041 ↗

Phase 0 Recruiting 19 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSequentialOpen-labelTreatment

Summary

This is an open-label, dose escalation, phase I study to evaluate safety tolerability, MTD or MFD, pharmacokinetic profile, immunogenicity, and pharmacodynamic profile of IDOV-SAFETM in patients with advanced solid tumors.

Timeline

Start
2024-04-12
Primary completion
2025-12-31
Completion
2026-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject IDOV-SAFETM Other / unclassified 1e+09 unknown Intravenous
Subject IDOV-SAFETM Other / unclassified 3e+09 unknown Intravenous
Subject IDOV-SAFETM Other / unclassified 1e+10 unknown Intravenous
Subject IDOV-SAFETM Other / unclassified 3e+10 unknown Intravenous

Indications

neoplasm